

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Mon, 24 Feb 2020 17:21:34 +0000  
**To:** Van Hoof, Johan [JRDBE];Erbelding, Emily (NIH/NIAID) [E]  
**Cc:** Stoffels, Paul [JJCUS]  
**Subject:** RE: as26 based COVID-19 vaccine candidate

Johan:

Thanks for the note. I enjoyed and learned from your presentation this morning. The best way to keep in touch with NIAID would be through Emily and Barney.

Best regards,.

Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Van Hoof, Johan [JRDBE] (b) (6)  
**Sent:** Monday, February 24, 2020 11:58 AM  
**To:** Erbelding, Emily (NIH/NIAID) [E] (b) (6)>  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) Stoffels, Paul [JJCUS] (b) (6)  
**Subject:** as26 based COVID-19 vaccine candidate

Dear Emily,

Dear Dr. Fauci,

First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points I noted from our discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with NIAID.

Looking forward to your feedback,